HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Zbigniew Morawiec Selected Research

Triple Negative Breast Neoplasms

5/2014Association of microRNAs and pathologic response to preoperative chemotherapy in triple negative breast cancer: preliminary report.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Zbigniew Morawiec Research Topics

Disease

21Breast Neoplasms (Breast Cancer)
01/2018 - 01/2003
15Neoplasms (Cancer)
01/2018 - 10/2004
3Neoplasm Metastasis (Metastasis)
07/2016 - 01/2006
3Genomic Instability
12/2010 - 01/2003
2Pathologic Complete Response
07/2012 - 05/2012
2Leukemia
07/2008 - 11/2006
2Stomach Neoplasms (Stomach Cancer)
10/2006 - 01/2006
1Ductal Carcinoma
07/2016
1Triple Negative Breast Neoplasms
05/2014
1Margins of Excision
02/2014
1Rectal Neoplasms (Rectal Cancer)
12/2012
1Fever of Unknown Origin
12/2012
1Wounds and Injuries (Trauma)
12/2012
1Lymphatic Metastasis
12/2008
1Rhabdomyosarcoma
08/2008
1Sarcoma (Soft Tissue Sarcoma)
08/2008
1BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)
07/2008
1Carcinoma (Carcinomatosis)
06/2007
1Infections
01/2006

Drug/Important Bio-Agent (IBA)

10DNA (Deoxyribonucleic Acid)IBA
12/2010 - 01/2003
3EnzymesIBA
10/2015 - 12/2010
3Estrogens (Estrogen)FDA Link
08/2009 - 01/2006
3Progesterone Receptors (Progesterone Receptor)IBA
08/2009 - 01/2006
3Hydrogen Peroxide (Hydroperoxide)FDA LinkGeneric
01/2008 - 10/2004
3MutagensIBA
10/2006 - 10/2004
2Messenger RNA (mRNA)IBA
01/2018 - 07/2016
2Hormones (Hormone)IBA
10/2016 - 12/2007
2Matrix Metalloproteinases (MMPs)IBA
07/2016 - 01/2006
2AntioxidantsIBA
10/2015 - 07/2007
2MicroRNAs (MicroRNA)IBA
09/2014 - 05/2014
2Proteins (Proteins, Gene)FDA Link
01/2014 - 01/2003
2TamoxifenFDA LinkGeneric
08/2008 - 07/2007
2Pharmaceutical PreparationsIBA
08/2008 - 10/2004
2Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
07/2008 - 11/2006
2Imatinib Mesylate (Gleevec)FDA Link
07/2008 - 11/2006
2Methylnitronitrosoguanidine (MNNG)IBA
01/2008 - 01/2006
2Codon (Codons)IBA
06/2007 - 12/2005
1Estrogen Receptor alphaIBA
01/2018
1Estrogen ReceptorsIBA
01/2018
1Glutathione Peroxidase GPX1IBA
01/2018
1Biological ProductsIBA
10/2016
1Cysteine Proteases (Cysteine Protease)IBA
10/2016
1Ceruloplasmin (Ferroxidase)IBA
10/2015
1Thiobarbituric Acid Reactive SubstancesIBA
10/2015
1prolyl-proline (Pro-Pro)IBA
10/2015
1Glutathione PeroxidaseIBA
10/2015
1Trace Elements (Biometals)IBA
10/2015
1SeleniumIBA
10/2015
1Programmed Cell Death 1 ReceptorIBA
08/2015
1CTLA-4 AntigenIBA
08/2015
1Phenobarbital (Luminal)FDA Link
02/2014
1Anti-Bacterial Agents (Antibiotics)IBA
12/2012
1Gentamicins (Gentamicin)FDA LinkGeneric
12/2012
1Caspase 3 (Caspase-3)IBA
07/2012
1AnthracyclinesIBA
07/2012
1Cytochrome P-450 CYP2D6 (CYP2D6)IBA
07/2012
1Biomarkers (Surrogate Marker)IBA
07/2012
1Transforming Growth Factor beta3 (TGF beta 3)IBA
07/2012
1Taxoids (Taxanes)IBA
07/2012
1Cisplatin (Platino)FDA LinkGeneric
05/2012
1NucleotidesIBA
10/2010
1lysyllysine (Lys-Lys)IBA
12/2008
1Anastrozole (Arimidex)FDA LinkGeneric
08/2008
1MelatoninIBA
12/2007
1Amifostine (Ethyol)FDA LinkGeneric
07/2007
1Free RadicalsIBA
07/2007
1AlkaliesIBA
07/2007
1prolylarginineIBA
06/2007
1DNA Polymerase beta (DNA Polymerase IV)IBA
06/2007
1methionylmethionine (Met-Met)IBA
06/2007
1CarcinogensIBA
01/2006
1AntigensIBA
01/2006
1NitrosaminesIBA
01/2006
1Doxorubicin (Adriamycin)FDA LinkGeneric
10/2004
15' Untranslated Regions (5' UTR)IBA
01/2003

Therapy/Procedure

3Drug Therapy (Chemotherapy)
09/2014 - 10/2004
3Therapeutics
05/2014 - 12/2012
2Neoadjuvant Therapy
07/2012 - 05/2012
1Adjuvant Chemotherapy
02/2014
1Radiotherapy
02/2014
1Proctectomy
12/2012
1Chemoprevention
07/2007
1Aftercare (After-Treatment)
10/2004